Literature DB >> 23352435

Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.

Catharina M Korse1, Babs G Taal, Marie-Louise F van Velthuysen, Otto Visser.   

Abstract

PURPOSE: Epidemiological studies on neuroendocrine tumours (NETs) generally show a major increase in incidence. To investigate this increase, epidemiological data from the Netherlands were evaluated according to histological grade.
METHODS: All 47,800 patients with NET (diagnosed 1990-2010) from the population-based Netherlands Cancer Registry were stratified according to the latest World Health Organization (WHO) classification for the digestive system: well-differentiated NET grade 1 and 2 (G1NET and G2NET), and poorly differentiated (grade 3) neuroendocrine carcinoma, subdivided into large cell (G3-LCNEC) and small cell (G3-SCNEC).
RESULTS: The age-standardised incidence rate (excluding G3-SCNEC) increased from 2.1/100,000 in 1990 to 4.9/100,000 in 2010. The incidence of G1NET increased from 2.0 to 3.0; there was a large increase in G2NET from 0.01 in 1990 to 0.2 in 2010, and of the G3-LCNEC from 0.01 to 1.8, respectively. In G3-SCNEC incidence in men decreased from 21.3 to 10.1, whereas in women it increased from 4.5 to 7.7. The 5-year survival improved in G1NET, particularly for metastatic disease, from 30% in 1990-2000 to 47% in 2001-2010.
CONCLUSION: The increasing incidence of NET (without G3-SCNEC) was mainly due to the increase of G3-LCNEC. This increase is related to improved diagnostic procedures and to shifting in pathology from other entities (such as undifferentiated carcinoma) to NET. Improved survival was seen in all sites and stages, especially in patients with metastatic G1NET. Because of its influence on incidence and survival, we recommend to present epidemiological studies on NET according to histological classification.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23352435     DOI: 10.1016/j.ejca.2012.12.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  61 in total

Review 1.  The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database.

Authors:  Pier Luigi Filosso; Pierre Emmanuel Falcoz; Paolo Solidoro; Danilo Pellicano; Stefano Passani; Francesco Guerrera; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 2.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

3.  Is the clinical course of laryngeal typical carcinoid tumor indolent?

Authors:  Alfio Ferlito; Kenneth O Devaney; Jennifer L Hunt; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-09-08       Impact factor: 2.503

Review 4.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

5.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 6.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

7.  Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.

Authors:  Scott K Sherman; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

8.  Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Clin Exp Metastasis       Date:  2014-09-21       Impact factor: 5.150

9.  Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Authors:  Barbara Nuñez-Valdovinos; Alberto Carmona-Bayonas; Paula Jimenez-Fonseca; Jaume Capdevila; Ángel Castaño-Pascual; Marta Benavent; Jose Javier Pi Barrio; Alex Teule; Vicente Alonso; Ana Custodio; Monica Marazuela; Ángel Segura; Adolfo Beguiristain; Marta Llanos; Maria Purificacion Martinez Del Prado; Jose Angel Diaz-Perez; Daniel Castellano; Isabel Sevilla; Carlos Lopez; Teresa Alonso; Rocio Garcia-Carbonero
Journal:  Oncologist       Date:  2018-01-12

10.  High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.

Authors:  Bruno Conte; Ben George; Michael Overman; Jeannelyn Estrella; Zhi-Qin Jiang; Amir Mehrvarz Sarshekeh; Renata Ferrarotto; Paulo M Hoff; Asif Rashid; James C Yao; Scott Kopetz; Arvind Dasari
Journal:  Clin Colorectal Cancer       Date:  2015-12-29       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.